Gain Therapeutics (NASDAQ:GANX) Earns “Buy” Rating from HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 298.01% from the stock’s previous close.

GANX has been the topic of several other research reports. Scotiabank began coverage on Gain Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price target on the stock. Chardan Capital restated a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a report on Friday, March 28th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Stock Up 11.0%

NASDAQ GANX opened at $2.01 on Monday. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $3.19. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The business’s fifty day simple moving average is $1.94 and its 200-day simple moving average is $2.01. The firm has a market cap of $59.15 million, a PE ratio of -1.83 and a beta of 0.17.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). As a group, equities analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current year.

Institutional Trading of Gain Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Benedict Financial Advisors Inc. acquired a new position in Gain Therapeutics in the 4th quarter valued at about $35,000. Sprott Inc. acquired a new position in Gain Therapeutics in the 4th quarter valued at about $30,000. Jones Financial Companies Lllp grew its position in Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after acquiring an additional 44,750 shares in the last quarter. Marshall Wace LLP acquired a new position in Gain Therapeutics in the 4th quarter valued at about $198,000. Finally, Northern Trust Corp grew its position in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares in the last quarter. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.